



Zeal & Innovation in Medicine

Ref : ZLL/Compliance/LODR

Date : 07.07.2020

BSE Limited,  
Compliance Department,  
P. J. Towers, Dalal Street,  
MUMBAI – 400 001  
Company Code – 541400

Dear Sirs,

**Sub : Press Release for Submission of Marketing Authorization Application for Rizatriptan orally dissolving film in Europe**

Please find enclosed herewith our Press Release relating to Marketing Authorization Application for Rizatriptan orally dissolving film in Europe.

This is for your information and record.

Thanking you,

Yours faithfully,  
For ZIM LABORATORIES LIMITED

(Piyush Nikhade)  
Company Secretary and Compliance Officer



Encl : As above.

**ZIM LABORATORIES LIMITED**

[www.zimlab.in](http://www.zimlab.in) | [info@zimlab.in](mailto:info@zimlab.in) | CIN : L99999MH1984PLC032172

Works : B-21/22, MIDC Area, Kalmeshwar – 441 501 Dist. Nagpur  
Maharashtra, India. Ph. +91.718.271370 | Fax : +091.7118.271470

Regd. Office : Sadoday Gyan (Ground Floor), Opp. NADT, Nelson Square,  
Nagpur – 440013. Maharashtra, India. Ph. +091.712.2588070



## **ZIM Announces Submission of Marketing Authorization Application for Rizatriptan orally dissolving film in Europe**

Nagpur, India; 7 July, 2020

ZIM Laboratories Limited (ZIM) today announced that it has filed the regulatory dossier for approval of Rizatriptan orally dissolving film in Europe.

Rizatriptan orally dissolving film is a product developed using our **Thinoral®** technology which yields instantly wettable, rapidly dissolving, and stable films. The product is used in the treatment of migraine which is invariably associated with symptoms like nausea and vomiting. The fast dissolving feature provides faster onset of action, and the flexible nature of film dosage form allows for convenience in carrying. As the presently available comparable product in the market is a mouth dissolving tablet which is extremely fragile, ZIM's product offering is likely to provide significant advantage to patients in portability as well as faster action.

"The submission of the Rizatriptan orally dissolving film MAA represents a critical milestone for ZIM and for European patients suffering from Migraine. This submission puts us one step closer to creating a portfolio of various therapeutic products that target patient convenience and treatment adherence for special need population." said Dr. Anwar Daud, Managing Director of ZIM Laboratories Limited. "Securing a regulatory approval for our Thinoral® technology based products in Europe will be an important step in our overall commercialization strategy for this technology. And positioning ZIM as an important player in the complex generics sphere."

### **About ZIM laboratories Limited**

ZIM is an innovative drug delivery solution provider focusing on improving patient convenience and adherence to drug intake. We offer a range of technology-based drug delivery solutions and non-infringing proprietary manufacturing processes for the production and supply of innovative and differentiated generic pharmaceutical products to our customers globally. ZIM provides its customers with a comprehensive range of value-added solid dosage differentiated generic products in semi-finished and finished categories/formulations. These include granules, pellets (sustained, modified, extended-release), taste-masked powders, suspensions, tablets, capsules, and it's recently developed Oral Thin Films (OTF).